Autoimmune Diseases  >>  Betaseron (IFN-β-1b)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Betaseron (IFN-β-1b) / Bayer
NCT00893217: BEYOND Pilot Study

Completed
2
71
US
Betaseron (Interferon beta-1b, BAY86-5046)
Bayer
Multiple Sclerosis, Relapsing-Remitting
 
06/03
NCT00235989: Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Completed
2
63
US
Interferon beta 1b (Betaseron, BAY86-5046), Betaferon
Bayer
Multiple Sclerosis, Relapsing-Remitting
01/08
01/08
NCT00489489 / 2006-003134-14: Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis

Completed
2
118
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for Teriflunomide), Interferon-β, Avonex®, Rebif®, Betaseron®
Sanofi
Multiple Sclerosis
06/09
06/09
NCT00811395 / 2007-003997-24: Long Term Safety of Teriflunomide When Added to Interferon-Beta or Glatiramer Acetate in Patients With Multiple Sclerosis

Completed
2
182
US, Canada, Europe
Teriflunomide, HMR1726, Placebo (for teriflunomide), Interferon-β [IFN-β], Avonex®, Rebif®, Betaseron®, Glatiramer Acetate [GA], Copaxone®
Sanofi
Multiple Sclerosis
04/10
04/10
REPAIR, NCT01171209 / 2009-016824-29: REsPonse to Interferon-Alpha in InterfeRon-β Neutralizing Antibody Positive Multiple Sclerosis Patients

Completed
2
10
Europe
Interferon-beta and human leukocyte Interferon-α, IFN-beta : Rebif, Betaferon, IFN-alfa: Multiferon®
Melinda Magyari, University of Copenhagen
Multiple Sclerosis
06/11
08/11
TERIVA, NCT01403376 / 2011-001160-21: Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide

Checkmark AAN 2013
Jan 2013 - Jan 2013: AAN 2013
Completed
2
128
Canada, Europe, RoW
teriflunomide, HMR1726, Interferon-β-1, Rebif®, Avonex®, Betaseron®, Betaferon®, Extavia®, Genfaxone®, Influenza vaccine
Sanofi
Multiple Sclerosis
01/12
01/12

Download Options